ID   NYH/TPT
AC   CVCL_0B28
DR   Wikidata; Q54931219
RX   PubMed=7640225;
RX   PubMed=9062409;
CC   Selected for resistance to: ChEBI; CHEBI_63632; Topotecan.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_8207 ! GLC-2
SX   Male
AG   41Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 19-12-24; Version: 9
//
RX   PubMed=7640225; DOI=10.1038/bjc.1995.345; PMCID=PMC2034011;
RA   Sorensen, Morten
RA   Sehested, Maxwell
RA   Jensen, Peter Buhl
RT   "Characterisation of a human small-cell lung cancer cell line
RT   resistant to the DNA topoisomerase I-directed drug topotecan.";
RL   Br. J. Cancer 72:399-404(1995).
//
RX   PubMed=9062409; DOI=10.1038/bjc.1997.154; PMCID=PMC2063407;
RA   Jensen, Peter Buhl
RA   Holm, Bente
RA   Sorensen, Morten
RA   Christensen, Ib Jarle
RA   Sehested, Maxwell
RT   "In vitro cross-resistance and collateral sensitivity in seven
RT   resistant small-cell lung cancer cell lines: preclinical
RT   identification of suitable drug partners to taxotere, taxol, topotecan
RT   and gemcitabin.";
RL   Br. J. Cancer 75:869-877(1997).
//